BR0108096A - Method for maintaining or improving mucin synthesis - Google Patents

Method for maintaining or improving mucin synthesis

Info

Publication number
BR0108096A
BR0108096A BR0108096-2A BR0108096A BR0108096A BR 0108096 A BR0108096 A BR 0108096A BR 0108096 A BR0108096 A BR 0108096A BR 0108096 A BR0108096 A BR 0108096A
Authority
BR
Brazil
Prior art keywords
maintaining
improving
synthesis
mucin
disease states
Prior art date
Application number
BR0108096-2A
Other languages
Portuguese (pt)
Other versions
BRPI0108096B1 (en
Inventor
Olivier Ballevre
Paul-Andre Finot
Denis Breuille
Original Assignee
Nestle Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27052980&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0108096(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US09/774,814 external-priority patent/US6833350B2/en
Application filed by Nestle Sa filed Critical Nestle Sa
Publication of BR0108096A publication Critical patent/BR0108096A/en
Publication of BRPI0108096B1 publication Critical patent/BRPI0108096B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"MéTODO PARA MANTER OU MELHORAR A SìNTESE DE MUCINAS". Métodos para manter, melhorar ou aumentar a síntese de mucina administrando-se um suplemento ou composição nutricional que contém uma quantidade terapeuticamente eficaz de treonina são fornecidos. A presente invenção ainda fornece métodos para tratar diversos estados de doença caracterizados pelas alterações dos níveis de mucina, tal como, infecções bacterianas e inflamatórias intestinais ou outros tipos de estados de doença."METHOD FOR MAINTAINING OR IMPROVING THE SYNTHESIS OF MUCINES". Methods for maintaining, improving or increasing mucin synthesis by administering a nutritional supplement or composition that contains a therapeutically effective amount of threonine are provided. The present invention further provides methods for treating various disease states characterized by changes in mucin levels, such as intestinal bacterial and inflammatory infections or other types of disease states.

BRPI0108096A 2000-02-04 2001-01-31 uses of a protein source comprising amino acids wherein the threonine content is at least 5.5% by weight of amino acids BRPI0108096B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49890500A 2000-02-04 2000-02-04
US09/774,814 US6833350B2 (en) 2000-02-04 2001-01-30 Method for maintaining or improving the synthesis of mucins
PCT/EP2001/001013 WO2001056405A2 (en) 2000-02-04 2001-01-31 A method for maintaining or improving the synthesis of mucins

Publications (2)

Publication Number Publication Date
BR0108096A true BR0108096A (en) 2002-10-29
BRPI0108096B1 BRPI0108096B1 (en) 2017-05-09

Family

ID=27052980

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0108096A BRPI0108096B1 (en) 2000-02-04 2001-01-31 uses of a protein source comprising amino acids wherein the threonine content is at least 5.5% by weight of amino acids

Country Status (22)

Country Link
EP (1) EP1255452B2 (en)
JP (1) JP2003533436A (en)
CN (1) CN1434681B (en)
AT (1) ATE323422T1 (en)
AU (1) AU784137B2 (en)
BG (1) BG106967A (en)
BR (1) BRPI0108096B1 (en)
CA (1) CA2399063C (en)
CZ (1) CZ20022978A3 (en)
DE (1) DE60118888T3 (en)
DZ (1) DZ3298A1 (en)
ES (1) ES2261383T5 (en)
HR (1) HRP20020647A2 (en)
HU (1) HUP0204439A3 (en)
IL (1) IL150977A (en)
MA (1) MA25656A1 (en)
MX (1) MXPA02007491A (en)
NO (1) NO20023640L (en)
NZ (1) NZ520605A (en)
PL (1) PL357078A1 (en)
SK (1) SK11212002A3 (en)
WO (1) WO2001056405A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004112512A1 (en) 2003-06-23 2004-12-29 Nestec S.A. Amino acid supplementation for a healthy microbiota ecosystem
WO2007004613A1 (en) 2005-07-01 2007-01-11 Ajinomoto Co., Inc. THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASE AND TNF-α PRODUCTION INHIBITOR
RU2437655C2 (en) * 2006-01-09 2011-12-27 Нестек С.А. Treatment of patients exposed to stress
WO2012133198A1 (en) * 2011-03-25 2012-10-04 イーエヌ大塚製薬株式会社 Nutritional composition for inflammatory diseases
EP2734210B1 (en) 2011-07-22 2017-11-22 Abbott Laboratories Galactooligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
EP3167895A1 (en) * 2015-11-10 2017-05-17 University College Dublin A dietary supplement comprising beta-glucan and casein hydrolysate for improving health and growth performance in a mammal

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2459620B1 (en) * 1979-06-26 1983-08-05 Agronomique Inst Nat Rech TOTAL ENZYMATIC HYDROLISATE OF WHEY PROTEINS, OBTAINMENT AND APPLICATION
US5162373A (en) * 1986-01-17 1992-11-10 Board Of Regents, The University Of Texas System Methods and improved formulations for the determination and treatment of malignant disease in patients
JP2631470B2 (en) * 1987-05-15 1997-07-16 雪印乳業株式会社 Infection protective agent
CA1338682C (en) * 1988-12-23 1996-10-29 Gustavo Bounous Biologically active undenatured whey protein concentrate as food supplement
JP2805490B2 (en) * 1989-02-07 1998-09-30 雪印乳業株式会社 Bacterial toxin neutralizer
JP3007694B2 (en) * 1990-12-14 2000-02-07 雪印乳業株式会社 Pharmaceuticals and foods for preventing or treating gastric ulcer
WO1994014458A1 (en) * 1992-12-23 1994-07-07 Abbott Laboratories Medical foods for the nutritional support of infant/toddler metabolic diseases
NZ248605A (en) * 1993-05-28 1994-12-22 Abbott Lab Enteral nutritional product comprising protein and fat
FR2711529B1 (en) * 1993-10-28 1996-07-05 Clintec Nutrition Cy Composition based on amino acids intended for the treatment of an infection or an aggression causing an inflammatory reaction, in animals and in humans.
JPH07267855A (en) * 1994-03-30 1995-10-17 Taiho Yakuhin Kogyo Kk Glutamine producing agent
US5952314A (en) * 1994-04-01 1999-09-14 Demichele; Stephen Joseph Nutritional product for a person having ulcerative colitis
US5728678A (en) * 1995-06-06 1998-03-17 Nestec Ltd. Method and composition for providing nutrition to a renal failure patient
US5670157A (en) * 1995-12-11 1997-09-23 Nestec Ltd. Method for reducing and controlling immunoglobulin concentrations
US5922766A (en) * 1997-07-02 1999-07-13 Acosta; Phyllis J. B. Palatable elemental medical food
CA2300076A1 (en) * 1997-09-16 1999-03-25 Societe Des Produits Nestle S.A. Organ specific nutrition
CA2331921A1 (en) * 1998-06-24 1999-12-29 Boyce Thompson Institute For Plant Research, Inc. A novel invertebrate intestinal mucin cdna and related products and methods
EP1034704A1 (en) * 1999-03-12 2000-09-13 Societe Des Produits Nestle S.A. Nutritional composition intended for specific gastro-intestinal maturation in premature mammals
EP1222275A2 (en) * 1999-10-22 2002-07-17 The Board of Regents of the University of Nebraska Serum amyloid a isoform from colostrum

Also Published As

Publication number Publication date
NO20023640L (en) 2002-09-19
EP1255452B2 (en) 2010-03-03
HUP0204439A3 (en) 2004-12-28
WO2001056405A2 (en) 2001-08-09
CA2399063C (en) 2014-01-28
ES2261383T3 (en) 2010-06-14
NO20023640D0 (en) 2002-07-31
CN1434681B (en) 2010-12-08
JP2003533436A (en) 2003-11-11
MXPA02007491A (en) 2002-12-13
BRPI0108096B1 (en) 2017-05-09
HRP20020647A2 (en) 2004-12-31
DE60118888T2 (en) 2007-01-18
IL150977A (en) 2005-09-25
IL150977A0 (en) 2003-02-12
SK11212002A3 (en) 2003-01-09
EP1255452B1 (en) 2006-04-19
EP1255452A2 (en) 2002-11-13
MA25656A1 (en) 2002-12-31
ATE323422T1 (en) 2006-05-15
DE60118888D1 (en) 2006-05-24
CA2399063A1 (en) 2001-08-09
DZ3298A1 (en) 2001-08-09
BG106967A (en) 2003-04-30
NZ520605A (en) 2004-06-25
CN1434681A (en) 2003-08-06
CZ20022978A3 (en) 2003-02-12
PL357078A1 (en) 2004-07-12
AU4056401A (en) 2001-08-14
AU784137B2 (en) 2006-02-09
WO2001056405A3 (en) 2002-01-24
DE60118888T3 (en) 2010-09-23
HUP0204439A2 (en) 2003-04-28
ES2261383T5 (en) 2010-06-18

Similar Documents

Publication Publication Date Title
BR9710768A (en) Compound composition and processes for the treatment of bacterial infections in a host mammal in need of such treatment and for the preparation of 6-0-metilerithromycin form i
TW200503708A (en) Gyrase inhibitors and uses thereof
IL172773A (en) Formulations for the treatment of arthritis conditions
EP1562897A4 (en) Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer s disease
BR0208142A (en) Combinations comprising an antidiarrheal agent and epothilone or epothilone derivative
BRPI0510761A (en) methods of treating a patient afflicted with at least one condition and reducing or eliminating wrinkles
DE602004021644D1 (en) GYRASEINHIBITORS AND THEIR USES
MY138708A (en) Biaryloxymethylarenecarboxylic acids
BR0015698A (en) Compositions and methods for treating allergic diseases
BRPI0408882A (en) lactulose-containing compositions for treating rotavirus infections
BR0209128A (en) Compounds, pharmaceutical compositions, methods for treating pain, methods for modulating a pharmacological response and uses of compounds
BR9712141A (en) Application of 1-hyphroxy-2-pyridones to treat skin infections.
BR9911917A (en) Compositions comprising gaba and caffeine analogs
EP1178796A4 (en) Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
BRPI0413404A (en) pharmaceutical compositions, methods of treating or preventing cardiac dysfunction, methods of enhancing cardiac function, and identifying mif inhibitor
BRPI0409609A (en) reverse cholesterol transport mediators for the treatment of hypercholesterolemia
BR0108096A (en) Method for maintaining or improving mucin synthesis
IL113940A (en) Synthetic peptides which are elastase inhibitors and pharmaceutical compositions for the treatment of neutrophil associated inflammatory disease containing said inhibitors
BRPI0414139A (en) methods and compositions for treating herpes infections
BR0006301A (en) Antibacterial and prokinetic macrolides
YU58102A (en) A method for maintaining or improving the synthesis of mucins
BR0210063A (en) Stable composition and use
BRPI0519023A2 (en) pharmaceutical composition containing at least one dolastatin derivative 10
MX2020010425A (en) Isotopically modified composition and therapeutic uses thereof.
BR0311463A (en) Compositions comprising a dietzia bacterium that are useful for the treatment of paratuberculosis in ruminants and a method for culturing the bacterium.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O ART .8O COMBINADO COM ART. 13 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A23L 33/12 (2016.01)